Humana Inc.

HUM · NYSE · USD

Can Humana lift individual Medicare Advantage margins to at least 3% by 2028 while carrying its largest-ever member cohort through uncertain Stars scores and Medicare funding?

Last 4 earnings calls · through Q2 FY2026

Bull case

  • Membership growth and plan pricing

    The bull case is that Humana grew membership far faster than expected while pricing every plan to a real margin, so the added volume is not loss-leader growth.

  • New member cost performance

    Management says new and returning members are running in line with cost expectations, which would let margin improve as first-year acquisition costs fall away.

  • Cost control and care management

    If operational savings and clinical programs keep pace, the larger book should spread fixed costs and support a durable Medicare Advantage margin.

  • Medicaid and CenterWell diversification

    Medicaid contracts and CenterWell services grow alongside the insurance book, giving the company earnings that do not depend on the annual Medicare rate notice.

Bear case

  • CMS funding below cost trend

    The bear case is that government funding keeps arriving below medical cost trend, so Humana must cut benefits and exit plans and give back members it just won.

  • Stars payment threshold uncertainty

    Star ratings are scored against competitors rather than a fixed bar, so the promised return to top-quartile payment is a target the company cannot verify in advance.

  • Thin cash generation

    Cash generation is modest against revenue and returns are limited to offsetting dilution, leaving little cushion if the enlarged membership costs more than planned.

Bull and bear points

Growth & Execution

In short: Membership growth beat plan, but the 2027 bids cut benefits and exit plans to protect margin.

Bull · 3

  • New sales concentrate in 4-star plans

    Selling into higher-rated contracts means each new enrollee carries more revenue, which is what makes the growth worth having rather than just larger.

    Q4 FY2025 call

  • Stars gains widen across measured metrics

    Management once called the failing Stars year expected but disappointing; it now reports improvement outpacing its own five-year trend on most measures, pointing to operational recovery.

    Tone shiftQ3 FY2025 → Q2 FY2026

  • Medicaid wins add non-Medicare members

    Medicaid membership rose with January starts in new states, giving Humana revenue that does not depend on Medicare Advantage rate notices.

    Q1 FY2026 call
Bear · 2

  • Plan exits reduce the 2027 membership base

    Benefit changes and plan exits shrink the base Humana just paid to acquire, and management expects to recapture only part of that volume as it did in 2025.

    Q2 FY2026 call

  • Growth slips to third behind margin

    Management once said it would take as much retention-driven growth as it could; it now ranks growth a distant third behind margin and retention when it sets bids.

    Tone shiftQ3 FY2025 → Q1 FY2026

Profitability & Financial Strength

In short: Margins are thin and cash generation modest, with cost cuts and a Stars recovery carrying the improvement.

Bull · 2

  • Operating cost ratio falls with outsourcing

    The consolidated operating cost ratio dropped in the second quarter as Humana consolidated vendors and moved finance and HR work to outside partners.

    Q2 FY2026 call

  • Individual MA margin doubles before Stars

    Stripping out the Stars revenue loss, management expects individual Medicare Advantage pretax margin to double this year, which it treats as the underlying trend of the book.

    Q2 FY2026 call
Bear · 2

  • Free cash flow covers little of revenue

    Free cash flow of $1.9 billion over the last twelve months is 1.3% of revenue and below the prior year's $2.4 billion, limiting internal funding for growth and acquisitions.

    Filed financials

  • Stars headwind cuts profit across the year

    The Stars revenue loss for 2026 is about $3.5 billion after offsets, and management expects individual Medicare Advantage margin to sit slightly below breakeven this year.

    Q4 FY2025 call

Market Position

In short: Medicare Advantage dominates revenue, so CMS rates and industry Stars cut points decide much of the result.

Bull · 2

  • Contract diversification lowers single-plan risk

    Membership had concentrated in one contract at roughly 43% to 45% of the book; spreading members across more plans reduces how much one weak rating can cost.

    Q3 FY2025 call

  • Value-based providers show better cost trend

    Management says members cared for by value-based providers run at the better end of its cost range, evidence the care model manages utilization rather than only adding revenue.

    Q2 FY2026 call
Bear · 3

  • CMS rate increases trail medical cost trend

    Management says the funding gap is wider going into the 2027 bid season than a year earlier, which pushes the difference onto benefits and plan design.

    Q1 FY2026 call

  • Stars cut points are set by the industry

    Humana sees its own measures but not the thresholds, so whether it reaches top-quartile payment depends on how competitors perform as much as on its own gains.

    Q2 FY2026 call

  • Benefit stability gives way to plan exits

    Management pitched stable core benefits as the way to hold members; it now says it pushed harder on benefits and plan exits to reach its margin targets.

    Tone shiftQ3 FY2025 → Q2 FY2026